GLIOMATCH is a Horizon Europe project in research and innovation for improving the clinical outcome of malignant brain tumours in adults and children with tailored immunotherapy treatments.

Adult glioblastoma (GBM) and pediatric high-grade gliomas (pHGG, including diffuse midline gliomas) are highly malignant, intrinsically resistant and inevitably recurring brain tumours with dismal prognosis despite intensive treatment. The GLIOMATCH project aims at improving the clinical outcome of GBM/pHGG patients by enabling immunology-based patient stratification to empower personalised matching of appropriate existing/novel immunotherapy strategies, while improving follow-up of clinical responses to existing/novel therapeutics.

This will be achieved by integrating spatially resolved, multi-layered tissue maps (using integrated spatially resolved single-cell multiomics combining RNA/protein/(epi)genome insights) with non-invasive MRI images into a novel MRI radio-multiomics hub. This hub will revolutionise the clinical care of GBM/pHGG patients by providing an accessible and scalable tumour-host based patient stratification tool for personalised therapy matching, while enabling longitudinal follow-up to estimate (early) treatment efficacy or adverse effects.

AIDA Data Hub supports the Swedish contributions to GLIOMATCH pediatric cohort by providing data collaboration spaces on its data science platform to facilitate national data collection and harmonisation, and sharing with the AIDA community for clinical AI research and innovation in medical imaging diagnostics. The Swedish contribution to GLIOMATCH is led by Uppsala University.

Contacts

	Joel Hedlund Head of AIDA Data Hub Management, Policy support, System design support, Data sharing, Economy
	Pontus Freyhult IT Architect System design support, Policy support, Management, System development
	Claes Lundström Platform Scientific Director Management